Recent Finacing
Recent Raise
CoLucid Pharmaceuticals develops oral and IV lasmiditan for acute migraine, conducts Phase 2/3 clinical programs COL MIG-301 (SAMURAI), advances CNS preclinical candidates, and partners with ILDONG in Asia.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors